World's Best Scientists 2026 revealed!
Charles Erlichman

Charles Erlichman

D-Index & Metrics

Medicine

D-Index
82
Citations
22359
World Ranking
16232
National Ranking
8160

Overview

Charles Erlichman is affiliated with the Mayo Clinic in the United States and has a research focus in the field of medicine, with a particular emphasis on oncology. Their work spans multiple subfields including oncology, pathology and forensic medicine, molecular biology, epidemiology, and endocrinology, diabetes, and metabolism.

The scientist has contributed to research topics that include colorectal cancer treatments and studies, genetic factors in colorectal cancer, colorectal cancer screening and detection, neuroendocrine tumor research advances, thyroid cancer diagnosis and treatment, salivary gland tumors diagnosis and treatment, and ear and head tumors.

Frequent coauthors collaborating with Charles Erlichman include Jack Fiskum, Julien Taïeb, Greg Yothers, Richard M. Goldberg, and Takayuki Yoshino.

They have published in a variety of scientific journals, among which the most frequent venues are:

  • Journal of Clinical Oncology
  • JNCI Journal of the National Cancer Institute
  • Thyroid
  • Cancer
  • Pancreatology

Representative recent papers by Charles Erlichman include:

  • Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials, 2020, Journal of Clinical Oncology
  • Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database, 2021, JNCI Journal of the National Cancer Institute
  • An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer, 2020, Thyroid
  • Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination, 2020, Pancreatology
  • A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104), 2023, Cancer

Best Publications

  • A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.

    C Erlichman;S Fine;A Wong;T Elhakim

  • Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer

    Philip A. Philip;Michelle R. Mahoney;Cristine Allmer;James Thomas

  • Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

    Keith C Bible;Vera J Suman;Julian R Molina;Robert C Smallridge

  • Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.

    M J O'Connell;J A Laurie;M Kahn;R J Fitzgibbons

  • A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

    I F Tannock;N F Boyd;G DeBoer;C Erlichman

  • The Hsp90 chaperone complex as a novel target for cancer therapy

    M. P. Goetz;D. O. Toft;M. M. Ames;Charles Erlichman

  • Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

    Stephen M. Ansell;Sara A. Hurvitz;Patricia A. Koenig;Betsy R. LaPlant

  • Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer

    Philip A. Philip;Michelle R. Mahoney;Cristine Allmer;James Thomas

  • Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer

    Matthew P. Goetz;David Toft;Joel Reid;Matthew Ames

  • A Phase I Trial of the Farnesyl Transferase Inhibitor SCH66336: Evidence for Biological and Clinical Activity

    Alex A. Adjei;Charles Erlichman;Jenny N. Davis;David L. Cutler

  • Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

    Brigette B.Y. Ma;Wan Teck Lim;Boon Cher Goh;Edwin P. Hui

  • The HER Tyrosine Kinase Inhibitor CI1033 Enhances Cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and Topotecan by Inhibiting Breast Cancer Resistance Protein-mediated Drug Efflux

    Charles Erlichman;Scott A. Boerner;Christopher G. Hallgren;Rebecca Spieker

  • Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

    Sam J. Lubner;Michelle R. Mahoney;Jill L. Kolesar;Noelle K. LoConte

  • A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

    Manuel Hidalgo;Jan C. Buckner;Charles Erlichman;Marilyn S. Pollack

  • Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

    Shaji K. Kumar;Betsy LaPlant;Wee Joo Chng;Jeffrey Zonder

  • Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer

    Alex A. Adjei;Ann Mauer;Laura Bruzek;Randolph S. Marks

  • In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

    Paul Haluska;Joan M. Carboni;David A. Loegering;Francis Y. Lee

  • A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

    Elisabeth I. Heath;David W. Hillman;Ulka Vaishampayan;Shijie Sheng

  • Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Tim G. Call;Clive S. Zent;Betsy LaPlant

  • Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group

    Winnie Yeo;Hyun C. Chung;Stephen L. Chan;Ling Z. Wang

Frequent Co-Authors

Alex A. Adjei
Alex A. Adjei Cleveland Clinic
Jeff A. Sloan
Jeff A. Sloan Mayo Clinic
Joseph Rubin
Joseph Rubin Mayo Clinic
Matthew P. Goetz
Matthew P. Goetz Mayo Clinic
Richard M. Goldberg
Richard M. Goldberg West Virginia University
Henry C. Pitot
Henry C. Pitot University of Wisconsin–Madison
Vera J. Suman
Vera J. Suman Mayo Clinic
Ross C. Donehower
Ross C. Donehower Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond a traditional medical degree, there are many flexible options in the USA. If you’re considering nursing but don’t have a nursing background, online direct entry msn programs for non-nurses provide a fast-track pathway to advanced nursing roles.

Some aspiring nurses seek accessible education options. You can explore the easiest nursing schools to get into to find programs with higher acceptance rates and less competitive entry requirements.

For those drawn to the administrative side of healthcare, medical billing and coding is an in-demand career. If cost is a concern, you may wonder, can you get financial aid for medical billing and coding? Many accredited online programs do offer financial assistance.

If entrance exams are a barrier, look for a nursing school that don't require teas and other standardized tests. These schools offer alternative pathways into the nursing profession, making healthcare more accessible for a wider range of students.

Best Scientists Citing Charles Erlichman

Trending Scientists

Recently Published Articles